Regulatory agencies (such as UNOS, CAP, ASHI, and CLIA) require that a prospective crossmatch test be performed using a serum sample not less than 14 days old prior to the scheduled transplant. The lymphocyte crossmatch assesses the level of circulating antibodies in the potential recipient that are directed against HLA Class I and/or Class II molecules of the donor.
Interpretive report provided.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
- HLA Crossmatch Flow
- Flow Crossmatch, Donor
- Kidney Transplant Final Crossmatch
- Living Final Pre-Txp, Donor
- HLA REPORT
- TISSUE TYPING
Collect specimen in sufficient yellow top (ACD) solution A tubes. Send intact specimen at room temperature. Do not refrigerate or freeze. Testing must be performed within 14 days prior to transplant.
Note: Required: Additional material is required from patient.
For Allo-Crossmatch order: "Solid Organ Transplant Allo-Crossmatch (HLA)"
For Endothelial Precursor Cross-match order. "Solid Organ Transplant - Endothelial Precursor Cell Cross-match (HLA)".
Test will include additional crossmatch testing if indicated. By ordering this test the clinician acknowledges that additional reflex testing will be performed and billed at a separate additional charge if indicated. The Flow Crossmatch uses indirect immunofluorescence to detect human alloantibodies bound to target lymphocytes. IgG antibodies appear to be most associated with rejection; therefore a fluorophore cojugated anti human IgG reagent is used to detect the alloantibody binding. A second and third fluorescent parameter is used to delineate the desired cell population (T or B cell). Interpretation of the Flow Crossmatch is done by comparing the fluorescence intensity of the donor’s cells mixed with the patient's serum to the fluorescence intensity of the same donor when mixed with a known negative control serum. This fluorescent value is then converted mathematically into Median Channel Shift (MCS) or Molecules of Equivalent Soluble Fluorochrome (MESF). The final pre-transplant flow crossmatch is evaluated along with the patient’s current antibody screening results and reviewed for concordance.